Telix Pharmaceuticals Ltd
For the period ended Apr 15, 2025. Filed Apr 17, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Apr 15, 2025 · Filed Apr 17, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · TLX101 Development Program and Registration-Enabling Study Update
TLX101 Development Program and Registration-Enabling Study Update
Telix continues to investigate TLX101 in front-line and recurrent settings. IPAX-2, a Phase 1/2 study in front-line glioblastoma in combination with standard of care and using TLX101-CDx as a companion diagnostic, continues to recruit patients.
Telix has submitted for ethics approval a registration-enabling study of TLX101 in recurrent glioblastoma. Subject to approval this will enable patient enrolment to commence at Australian sites in H2 2025, ahead of international expansion. Following the successful pre-IND 9 meeting with the U.S. Food and Drug Administration (FDA) in Q4 2024, the Company is also on track to submit an IND application in H1 2025, with the goal of commencing the study at U.S. sites in H2 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.